hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06351865, orgStudyIdInfo id: PHU/2023/21, briefTitle: Feasibility Study to Evaluate the Use of Patient Reported Complications After Digital Consent, acronym: PRC, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2024-09-19, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Portsmouth Hospitals NHS Trust, class: OTHER_GOV, collaborators name: University of East Anglia, descriptionModule briefSummary: Patient report complication data to our best knowledge has not been studied yet in electronic consent. This study is a feasibility study to assess whether patients will reliably report their complications, the quality of this reporting and whether the information provided in the consent form matches up to their experience. This data will then be used to improve the consent process and evaluate whether the Patient Initiated Follow Up (PIFU) model is effective or if it leads to underreporting of problems., conditionsModule conditions: Breast Cancer, conditions: Complication of Surgical Procedure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: Proportion of patients who respond to the feedback questionnaire, primaryOutcomes measure: Final attrition rate, secondaryOutcomes measure: Quoted risks in the consent to the incidence of complications, secondaryOutcomes measure: Frequency of PRC and CRCs (Consent Form Reported Complications), secondaryOutcomes measure: Understanding of consent, secondaryOutcomes measure: Language used in patient reported complications, secondaryOutcomes measure: Accuracy of potential complications, secondaryOutcomes measure: Participant preparation for surgery, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Queen Alexandra Hospital, status: RECRUITING, city: Portsmouth, state: Hampshire, zip: PO6 3LY, country: United Kingdom, contacts name: Edward St John, role: CONTACT, phone: 02392286000, email: edward.stjohn@porthosp.nhs.uk, geoPoint lat: 50.79899, lon: -1.09125, hasResults: False
protocolSection identificationModule nctId: NCT06351826, orgStudyIdInfo id: 22070876, briefTitle: Effectiveness of ELLASI Intervention Towards Polytrauma Patients in the Emergency Department, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-03, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Indonesia University, class: OTHER, descriptionModule briefSummary: This clinical trial aims to test the effectiveness of ELLASI intervention in response time, deterioration score, and metabolic status of polytrauma patients in the emergency department. The main questions it aims to answer are:1. Is the response time of polytrauma patients who receive ELLASI in the intervention group faster than the control group?2. Is the deterioration score of polytrauma patients who receive ELLASI in the intervention group better than the control group?3. Is the metabolic status of polytrauma patients who receive ELLASI in the intervention group better than the control group?Polytrauma patients in the intervention group will receive ELLASI, a structured intervention consisting of the six following:1. Evaluation of airway and cervical control, remove the foreign body, fluid, etc., from the airway,2. Patient positioning and giving oxygen, head-up,3. Stabilisation, including IV insertion, applying pressure and bandage, place monitor, and haemodynamic monitoring4. Assessment: re-assessment of pain and other main complaints5. Make sure informed consents are documented6. Inform patient and family for further interventionPolytrauma patients in the control group will receive the usual/standard intervention.Response time, early warning score, and arterial blood gas of polytrauma patients from both groups will be obtained and documented before and after the intervention., conditionsModule conditions: Polytrauma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 48, type: ESTIMATED, armsInterventionsModule interventions name: ELLASI, interventions name: Standard, outcomesModule primaryOutcomes measure: Response time, primaryOutcomes measure: Deterioration score, primaryOutcomes measure: Acidic Level (pH), primaryOutcomes measure: Base Excess (BE), primaryOutcomes measure: Bicarbonate level (HCO3), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: RSCM, status: RECRUITING, city: Jakarta Pusat, state: Jawa Barat, zip: 10430, country: Indonesia, contacts name: RSCM, role: CONTACT, phone: 062211500135, email: info@rscm.co.id, geoPoint lat: -6.1818, lon: 106.8223, hasResults: False
protocolSection identificationModule nctId: NCT06351813, orgStudyIdInfo id: B2024-029R, briefTitle: Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2026-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Shanghai Zhongshan Hospital, class: OTHER, collaborators name: Zhongshan Hospital (Xiamen), Fudan University, collaborators name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, descriptionModule briefSummary: The aim of this study was to identify and validate novel biomarkers for predict acute kidney injury (AKI) subphenotype, major adverse kidney events and other poor outcomes., conditionsModule conditions: Acute Kidney Injury, conditions: Critical Illness, conditions: Kidney Failure, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 358, type: ESTIMATED, outcomesModule primaryOutcomes measure: AKI nonresolving subphenotype, secondaryOutcomes measure: Major adverse kidney events at 30 days, secondaryOutcomes measure: Major adverse kidney events at 90 days, secondaryOutcomes measure: Major adverse kidney events at 365 days, secondaryOutcomes measure: Mortality, secondaryOutcomes measure: Receipt of renal replacement treatment, secondaryOutcomes measure: Moderate and severe AKI, secondaryOutcomes measure: AKI progression, secondaryOutcomes measure: Composite Outcome, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Shanghai Zhongshan Hospital, city: Shanghai, state: Shanghai, zip: 200032, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06351774, orgStudyIdInfo id: 21-F-45, briefTitle: Project AdaPT: An Adaptive Physiotherapy Intervention Augmented With a Healthy Mind Training Program for People With Chronic Low Back Pain, acronym: AdaPT, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-05-24, primaryCompletionDateStruct date: 2024-02-08, completionDateStruct date: 2024-03-25, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Ohio University, class: OTHER, collaborators name: University of Wisconsin, Madison, descriptionModule briefSummary: In the proposed research, we will elucidate the comparative effectiveness of standalone physiotherapy (PT) vs. PT augmented with a self-guided, app-based Healthy Minds Innovation wellbeing program (PT+HMI) aimed at cultivating awareness, connection, insight, and purpose for people with chronic low back pain (CLBP)., conditionsModule conditions: Back Pain Lower Back Chronic, conditions: Disability Physical, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: A 2 armed sequential, multiple-assignment randomized trial design, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, maskingDescription: The investigator was masked to the initial treatment assignment. The outcome assessor was not masked to treatment assignment and monitored treatment response at the mid-intervention in order to recommend continuation of current treatment or to augment treatment with the Healthy Mind Innovations training program for individuals who did not favorably respond to standalone PT., whoMasked: INVESTIGATOR, enrollmentInfo count: 13, type: ACTUAL, armsInterventionsModule interventions name: Physical therapy, outcomesModule primaryOutcomes measure: Oswestry Disability Index, primaryOutcomes measure: PROMIS Pain Interference, secondaryOutcomes measure: Actigraphy, secondaryOutcomes measure: 3D Motion Capture, secondaryOutcomes measure: Pain acceptance, secondaryOutcomes measure: Committed action, secondaryOutcomes measure: Healthy emotionality, secondaryOutcomes measure: Exercise behavior, secondaryOutcomes measure: Back pain screening tool 1, secondaryOutcomes measure: Back pain screening tool 1, secondaryOutcomes measure: Kinesiophobia, secondaryOutcomes measure: Attitudes towards complementary and alternative medicine, secondaryOutcomes measure: Treatment expectancy, secondaryOutcomes measure: Lumbar pressure pain threshold, secondaryOutcomes measure: Thermal method of limits, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ohio University, city: Athens, state: Ohio, zip: 45701, country: United States, geoPoint lat: 39.32924, lon: -82.10126, hasResults: False
protocolSection identificationModule nctId: NCT06351761, orgStudyIdInfo id: SCT02-ECG, briefTitle: WIBOFA - Validation of SCT02 With ECG-App for Detection of AF, acronym: WIBOFA, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-03, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Withings, class: INDUSTRY, descriptionModule briefSummary: The aim of the study is to evaluate the performance of Withings SCT02 with embedded Withings ECG-app in the automatic detection of atrial fibrillation, conditionsModule conditions: Atrial Fibrillation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 270, type: ESTIMATED, armsInterventionsModule interventions name: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording, interventions name: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording, outcomesModule primaryOutcomes measure: Co-primary outcome 1 - Sensitivity of Investigational Device, primaryOutcomes measure: Co-primary outcome 2 - Specificity of Investigational Device, secondaryOutcomes measure: Rhythm classification by ranges of heart rate, secondaryOutcomes measure: Quality of plots measured by the IMD - ECG Waveform Visibility, secondaryOutcomes measure: Quality of plots measured by the IMD - ECG Waveforms Polarity, secondaryOutcomes measure: Quality of plots measured by the IMD - ECG Waveforms Intervals, secondaryOutcomes measure: Quality of plots measured by the IMD - Heart Rate calculation, eligibilityModule sex: ALL, minimumAge: 22 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: FWD Clinical Research, city: Boca Raton, state: Florida, zip: 33486, country: United States, geoPoint lat: 26.3669, lon: -80.13033, locations facility: Diverse Clinical Research, city: Miami, state: Florida, zip: 33175, country: United States, geoPoint lat: 25.77427, lon: -80.19366, locations facility: Henri Mondor University Hospital, city: Créteil, state: Val De Marne, zip: 94000, country: France, geoPoint lat: 48.78333, lon: 2.46667, hasResults: False
protocolSection identificationModule nctId: NCT06351748, orgStudyIdInfo id: NN9535-7877, secondaryIdInfos id: U1111-1296-3151, type: OTHER, domain: World Health Organization (WHO), briefTitle: Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR), acronym: SCHOLAR, statusModule overallStatus: ENROLLING_BY_INVITATION, startDateStruct date: 2024-04-05, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Novo Nordisk A/S, class: INDUSTRY, descriptionModule briefSummary: This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide OW was listed in the National Reimbursement Drug List \[NRDL\] in China\] and 28 Feb 2023 (9 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this study. The study period will be 36 months prior to the first date of participants identification period., conditionsModule conditions: Diabetes Mellitus, Type 2, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 27000, type: ESTIMATED, armsInterventionsModule interventions name: Semaglutide, outcomesModule primaryOutcomes measure: Change in Haemoglobin A1c (HbA1c) level, primaryOutcomes measure: Change in HbA1c level, primaryOutcomes measure: Proportion of participants achieving HbA1c less than (<) 7.0%, secondaryOutcomes measure: Change in HbA1c level, secondaryOutcomes measure: Change in HbA1c level, secondaryOutcomes measure: Proportion of participants achieving HbA1c <7.0%, secondaryOutcomes measure: Change in body weight, secondaryOutcomes measure: Change in body weight, secondaryOutcomes measure: Description of participants with different demographic characteristics, secondaryOutcomes measure: Description of participants with different clinical characteristics, secondaryOutcomes measure: Proportion of participants with different antidiabetic medications, secondaryOutcomes measure: Proportion of participants with different non-antidiabetic medications, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tianjin Medical University Chu Hsien-I Memorial Hospital, city: Tianjin, country: China, geoPoint lat: 39.14222, lon: 117.17667, hasResults: False
protocolSection identificationModule nctId: NCT06351735, orgStudyIdInfo id: 2024-0336, briefTitle: Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in ALS Amyotrophic Lateral Sclerosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-05-01, completionDateStruct date: 2027-05-01, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Second Affiliated Hospital, School of Medicine, Zhejiang University, class: OTHER, descriptionModule briefSummary: Amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, affects motor neurons, causing progressive muscle atrophy and weakness. Current treatments are ineffective, with most patients dying within 3-5 years of diagnosis. The disease's exact cause is unclear, but factors such as oxidative stress and protein abnormalities are implicated. Abnormal protein deposits and neurotoxic factors in the brain and spinal cord contribute to ALS pathology. Recent research on the brain's glymphatic-lymphatic system suggests impaired waste clearance may exacerbate ALS. Restoring drainage connections between cervical lymphatic vessels and veins could potentially alleviate neurodegenerative disease progression., conditionsModule conditions: Evaluation of the Efficacy and Safety of Deep Cervical Lymph Node-vein Bypass Surgery in Patients With Amyotrophic Lateral Sclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CROSSOVER, timePerspective: PROSPECTIVE, enrollmentInfo count: 3, type: ESTIMATED, armsInterventionsModule interventions name: Deep cervical lymph node-vein bypass surgery, outcomesModule primaryOutcomes measure: ALSFRS-R scale, primaryOutcomes measure: Cognitive and Behavioral Scale (CAS), secondaryOutcomes measure: Baseline of slow vital capacity (SVC), secondaryOutcomes measure: Evaluation of glymphatic and meningeal lymphatic drainage, secondaryOutcomes measure: Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-5), eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06351722, orgStudyIdInfo id: smokingnlrp3inflasome, briefTitle: Non-surgical Periodontal Treatment in Smokers on SIRT-1, NLRP3 Inflammasome and LncRNAs, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-15, primaryCompletionDateStruct date: 2024-12-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Necmettin Erbakan University, class: OTHER, descriptionModule briefSummary: The goal of this observational is to analyze the relationship between levels of interleukin-18 (IL-18), interleukin (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), interleukin-10 (IL-10), transforming growth factor beta (TGF-β), Nucleotide-binding oligomerization domain -like receptor protein 3 (NLRP3), apoptosis-associated speck-like protein (ASC), caspase-1, Sirtuin 1 (SIRT-1), Long noncoding RNA (lncRNA) small nucleolar RNA host gene 5 (SNHG5), and maternally expressed gene 3 (MEG3) in saliva, serum, and peripheral mononuclear blood cell (PMBC)in patients with periodontitis and smokers, to examine the changes in these biomarkers after non surgical periodontal treatment (NSPT), and to evaluate potential confounders that may mediate this relationship.The main questions it aims to answer are:question 1: Is there a relationship between the biomarkers mentioned above and periodontitis and smoking? question 2:How do the above-mentioned biomarkers change after NSPT in smokers and non-smokers?, conditionsModule conditions: Periodontitis, Adult, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Before non-surgical periodontal treatment, interventions name: non-surgical periodontal treatment, interventions name: 3rd month after non-surgical periodontal treatment, outcomesModule primaryOutcomes measure: Pre-treatment clinical and laboratory evaluation, primaryOutcomes measure: Comparison of clinical measurements and laboratory measurements at 3 months post-treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06351709, orgStudyIdInfo id: UmutPaksoy, briefTitle: Acute Effects of Heat, Cold and Stretching on Knee Proprioception and Vertical Jump, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-11-02, primaryCompletionDateStruct date: 2021-02-20, completionDateStruct date: 2021-02-20, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-08, sponsorCollaboratorsModule leadSponsor name: Istanbul Bilgi University, class: OTHER, descriptionModule briefSummary: The aim of our study is to investigate the effects of heat, cold and stretching on knee proprioception and vertical jump. 60 healthy individuals were randomized into hot, cold, stretching and control groups of 15 each. Pre-test and post-test measurements were made immediately after the application. Knee proprioception was measured with a digital goniometer using the EPD (joint position sense) test. Vertical jump heights were measured with contact mat by countermovement (CMJ) and squat splash (SQS) tests., conditionsModule conditions: Healthy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Stretching, interventions name: Hot pack application, interventions name: Cold pack application, outcomesModule primaryOutcomes measure: Vertical Jump Distance Measurement, primaryOutcomes measure: Joint Position Sense Measurement, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 30 Years, stdAges: ADULT, contactsLocationsModule locations facility: İstanbul Medipan Tıp Merkezi, city: Istanbul, zip: 34218, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False
protocolSection identificationModule nctId: NCT06351696, orgStudyIdInfo id: 43008563, briefTitle: The Effects of Bromelain Supplement in Patients With Ulcerative Colitis, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-20, primaryCompletionDateStruct date: 2024-07-20, completionDateStruct date: 2024-08-10, studyFirstPostDateStruct date: 2024-04-08, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: National Nutrition and Food Technology Institute, class: OTHER, descriptionModule briefSummary: In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks.IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention., conditionsModule conditions: Ulcerative Colitis, conditions: Primary Sclerosing Cholangitis, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 84, type: ESTIMATED, armsInterventionsModule interventions name: Bromlein, interventions name: Placebo, outcomesModule primaryOutcomes measure: SCCAIQ, secondaryOutcomes measure: IBDQ, secondaryOutcomes measure: Serum TAC, secondaryOutcomes measure: Serum hsCRP, secondaryOutcomes measure: Serum TNF-a, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Azita Hekmatdoost, status: RECRUITING, city: Tehran, state: Middle East, zip: 19835, country: Iran, Islamic Republic of, contacts name: Azita Hekmatdoost, MD, PhD, role: CONTACT, phone: +989123065084, email: a_hekmat2000@yahoo.com, geoPoint lat: 35.69439, lon: 51.42151, hasResults: False